دورية أكاديمية
أعرض في EDS

GDF-15 Attenuates the Epithelium-Mesenchymal Transition and Alleviates TGFβ2-Induced Lens Opacity.

التفاصيل البيبلوغرافية
العنوان: GDF-15 Attenuates the Epithelium-Mesenchymal Transition and Alleviates TGFβ2-Induced Lens Opacity.
المؤلفون: Wang S; Department of Ophthalmology, Louis J. Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Chen CY; Department of Ophthalmology, Louis J. Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Liu CC; Department of Ophthalmology, Louis J. Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Stavropoulos D; Department of Ophthalmology, Louis J. Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Rao M; Department of Ophthalmology, Louis J. Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Petrash JM; Department of Ophthalmology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA., Chang KC; Department of Ophthalmology, Louis J. Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Neurobiology, Center of Neuroscience, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA, USA.; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
المصدر: Translational vision science & technology [Transl Vis Sci Technol] 2024 Jul 01; Vol. 13 (7), pp. 2.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Association for Research in Vision and Ophthalmology Country of Publication: United States NLM ID: 101595919 Publication Model: Print Cited Medium: Internet ISSN: 2164-2591 (Electronic) Linking ISSN: 21642591 NLM ISO Abbreviation: Transl Vis Sci Technol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Rockville, Md. : Association for Research in Vision and Ophthalmology
مواضيع طبية MeSH: Epithelial-Mesenchymal Transition*/drug effects , Transforming Growth Factor beta2*/metabolism , Transforming Growth Factor beta2*/pharmacology , Growth Differentiation Factor 15*/metabolism , Growth Differentiation Factor 15*/genetics , Cataract*/pathology , Cataract*/metabolism , Cataract*/prevention & control , Lens, Crystalline*/metabolism , Lens, Crystalline*/pathology , Lens, Crystalline*/drug effects, Animals ; Mice ; Mice, Inbred C57BL ; Cells, Cultured ; Disease Models, Animal ; Epithelial Cells/drug effects ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Blotting, Western ; Retinal Pigment Epithelium/drug effects ; Retinal Pigment Epithelium/pathology ; Retinal Pigment Epithelium/metabolism
مستخلص: Purpose: We sought to evaluate the efficacy of growth differentiation factor (GDF)-15 treatment for suppressing epithelial-mesenchymal transition (EMT) and alleviating transforming growth factor β2 (TGFβ2)-induced lens opacity.
Methods: To test whether GDF-15 is a molecule that prevents EMT, we pretreated the culture with GDF-15 in neural progenitor cells, retinal pigment epithelial cells, and lens epithelial cells and then treated with factors that promote EMT, GDF-11, and TGFβ2, respectively. To further investigate the efficacy of GDF-15 on alleviating lens opacity, we used mouse lens explant culture to mimic secondary cataracts. We pretreated the lens culture with GDF-15 and then added TGFβ2 to develop lens opacity (n = 3 for each group). Western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to measure EMT protein and gene expression, respectively.
Results: In cell culture, GDF-15 pretreatment significantly attenuated EMT marker expression in cultured cells induced by treatment with GDF-11 or TGFβ2. In the lens explant culture, GDF-15 pretreatment also reduced mouse lens opacity induced by exposure to TGFβ2.
Conclusions: Our results indicate that GDF-15 could alleviate TGFβ2-induced EMT and is a potential therapeutic agent to slow or prevent posterior capsular opacification (PCO) progression after cataract surgery.
Translational Relevance: Cataracts are the leading cause of blindness worldwide, with the only current treatment involving surgical removal of the lens and replacement with an artificial lens. However, PCO, also known as secondary cataract, is a common complication after cataract surgery. The development of an adjuvant that slows the progression of PCO will be beneficial to the field of anterior complications.
References: Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4679-87. (PMID: 17898292)
Chem Biol Interact. 2017 Oct 1;276:149-154. (PMID: 28137510)
Cells. 2022 Jul 29;11(15):. (PMID: 35954181)
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6762-9. (PMID: 26567788)
J Cataract Refract Surg. 2022 Feb 1;48(2):238-244. (PMID: 34538778)
Surgery. 2018 Aug;164(2):262-273. (PMID: 29731246)
Pharmaceuticals (Basel). 2020 Jan 16;13(1):. (PMID: 31963166)
Stem Cells Dev. 2015 Oct 15;24(20):2378-90. (PMID: 26154268)
Sci Rep. 2017 Apr 25;7(1):1117. (PMID: 28442786)
Exp Eye Res. 2011 Mar;92(3):173-9. (PMID: 21276793)
Curr Biol. 2019 Jun 17;29(12):1963-1975.e5. (PMID: 31155355)
J Clin Invest. 2009 Jun;119(6):1420-8. (PMID: 19487818)
Trends Endocrinol Metab. 2020 Dec;31(12):939-951. (PMID: 33172749)
Restor Neurol Neurosci. 2020;38(2):131-140. (PMID: 31815704)
J Am Intraocul Implant Soc. 1984 Spring;10(2):164-8. (PMID: 6547424)
Biomed Pharmacother. 2018 Jul;103:691-698. (PMID: 29680737)
Exp Eye Res. 2016 Jan;142:92-101. (PMID: 26003864)
Front Cell Neurosci. 2017 Dec 05;11:384. (PMID: 29259543)
Phytomedicine. 2020 Nov;78:153298. (PMID: 32781391)
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84. (PMID: 30459476)
Life Sci. 2021 Jan 15;265:118741. (PMID: 33181173)
JCI Insight. 2022 Aug 22;7(16):. (PMID: 35993367)
Neurodegener Dis. 2017;17(6):251-260. (PMID: 28787735)
Int J Ophthalmol. 2021 Jul 18;14(7):973-980. (PMID: 34282380)
Prim Care. 2015 Sep;42(3):409-23. (PMID: 26319346)
Eye (Lond). 2020 Aug;34(8):1357-1370. (PMID: 32055021)
Front Cell Dev Biol. 2020 Jun 25;8:501. (PMID: 32671066)
Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1410-8. (PMID: 9660489)
Nutrients. 2020 Oct 14;12(10):. (PMID: 33066702)
Prog Retin Eye Res. 2021 May;82:100905. (PMID: 32977000)
Br J Ophthalmol. 2012 May;96(5):614-8. (PMID: 22133988)
Biochem Biophys Res Commun. 2014 May 16;447(4):689-95. (PMID: 24755068)
BMC Public Health. 2022 Nov 12;22(1):2068. (PMID: 36369026)
Mol Biol Cell. 2005 Apr;16(4):1987-2002. (PMID: 15689496)
Int J Mol Sci. 2018 Oct 09;19(10):. (PMID: 30304871)
J Cell Biochem. 2018 Aug;119(8):6814-6827. (PMID: 29693273)
Biochem J. 2021 Jun 25;478(12):2285-2296. (PMID: 34143864)
Molecules. 2019 Mar 21;24(6):. (PMID: 30901941)
Prog Retin Eye Res. 2017 Sep;60:44-65. (PMID: 28807717)
Acta Pharmacol Sin. 2016 Jun;37(6):794-804. (PMID: 27133302)
Cell Stem Cell. 2018 Jun 01;22(6):834-849. (PMID: 29859174)
Invest Ophthalmol Vis Sci. 2021 Aug 2;62(10):24. (PMID: 34415985)
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352. (PMID: 32300252)
Brain Behav. 2022 Feb;12(2):e2502. (PMID: 35068064)
Nature. 2020 Feb;578(7795):444-448. (PMID: 31875646)
Invest Ophthalmol Vis Sci. 2013 Jan 14;54(1):323-32. (PMID: 23221074)
Med Hypothesis Discov Innov Ophthalmol. 2014 Summer;3(2):45-50. (PMID: 25738159)
معلومات مُعتمدة: P30 EY008098 United States EY NEI NIH HHS; R01 EY028147 United States EY NEI NIH HHS
المشرفين على المادة: 0 (Transforming Growth Factor beta2)
0 (Growth Differentiation Factor 15)
0 (Gdf15 protein, mouse)
تواريخ الأحداث: Date Created: 20240701 Date Completed: 20240701 Latest Revision: 20240705
رمز التحديث: 20240705
مُعرف محوري في PubMed: PMC11221611
DOI: 10.1167/tvst.13.7.2
PMID: 38949633
قاعدة البيانات: MEDLINE
الوصف
تدمد:2164-2591
DOI:10.1167/tvst.13.7.2